, Volume 19, Issue 5, pp 243-244

First online:

A note on the evaluation of BoNTA trial quality

  • Vance W. BergerAffiliated withBiometry Research Group, National Cancer Institute Email author 
  • , Diana KnollAffiliated withBiometry Research Group, National Cancer Institute

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


In their systematic review, Zhang et al. evaluate randomized controlled trials on the efficacy of Botulinum toxin type A (BoNTA) in helping patients with musculoskeletal disorders. Scoring each trial according to the Jadad scale they note that the studies range from 1 to 5 with an average of 4.1, which they interpret as a testimony of the high quality of the studies included. Unfortunately, we cannot share the author’s enthusiasm, as a perfect Jadad score of 5 is no guarantee that a study is of good quality.


Jadad score Randomized controlled trials Trial evaluation Trial quality Unmasking